Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.

Despite evidence on the burden of BMI >25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging.

This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI >25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.

Inclusion criteria

• Patient group

• Patient is aged ≥18 years at the time of survey completion.
• Patient has a BMI over 25 (self-reported)
• Patient is willing to participate in all study activities.
• Patient is able to read, write, and converse in English.
• Healthcare professional participant must meet the following criteria for inclusion in the study:

• HCP is aged ≥18 years at the time of survey completion.
• HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25
• HCP is willing to participate in all study activities.
• HCP is able to read, write, and converse in English.

Exclusion criteria

A participant who meets any of the following criteria will be excluded from the study:

• Participants do not have the cognitive capacity to provide informed consent.
• Participants with severe co-morbidity that might affect study participation.